Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.52 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.52 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.52 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | STK32B | Q9NY57 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695211 | 0.80 | PDGFRB (0.44) | PIM1LRRK2PIM3PIM2KDM5B | |
| SCHEMBL2693998 | 0.80 | HSP90AA1 (0.47) | KDM5BPDGFRBPDGFRAKDRCYP2A6 | |
| SCHEMBL17179205 | 0.72 | PIM1 (0.60) | PIM1BMPR1BPIK3C2GCDKL5TYK2 | |
| SCHEMBL15723924 | 0.71 | CYP2A6 (0.53) | SRCABL1PDGFRBPDGFRAPIK3CD | |
| SCHEMBL27010951 | 0.70 | LRRK2 (0.35) | PIM1TYK2CLK2DYRK1ALRRK2 | |
| SCHEMBL16200195 | 0.69 | PDGFRB (0.49) | PIM1BMPR1BPIK3C2GCDKL5TYK2 | |
| SCHEMBL883508 | 0.69 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL5292377 | 0.68 | PDGFRB (0.56) | PIM1BMPR1BPIK3C2GCDKL5TYK2 | |
| SCHEMBL462907 | 0.68 | PDGFRA (0.51) | PIM1LRRK2PIM3PIM2PDGFRB | |
| SCHEMBL1990603 | 0.68 | PIM1 (1.00) | PIM1BMPR1BPIK3C2GCDKL5TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273045-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2452940-B1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8779142-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2452940-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | PIM1 4623/4885BMPR1B 3081/4885PIK3C2G 2887/4885 |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | PIM1 4623/4885BMPR1B 3081/4885PIK3C2G 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.